FDA Cracks Down on Hims Drug Ads
- The FDA is cracking down on telehealth companies like Hims for potentially misleading advertising of weight loss injections (like Wegovy and Zepbound).
- * FDA Action: The FDA is taking action against companies advertising weight loss drugs in a potentially misleading way.
Here’s a summary of the article:
The FDA is cracking down on telehealth companies like Hims for potentially misleading advertising of weight loss injections (like Wegovy and Zepbound). These companies are selling “customized” doses of the drugs, even though the FDA states the approved versions are no longer in shortage (meaning compounding – creating custom doses – is no longer justified). Hims defends its practice, claiming it can benefit some patients. The FDA is implementing reforms to address deceptive drug advertising.
Key takeaways:
* FDA Action: The FDA is taking action against companies advertising weight loss drugs in a potentially misleading way.
* Compounding Issue: The issue centers around “compounding” drugs (creating custom doses) when FDA-approved versions are available.
* Hims’ Defense: Hims argues customized doses can be helpful for certain patients.
* advertising Reforms: The FDA is working on broader reforms to drug advertising.